Neuroimaging & Brain MeasuresEquity and EthicsDMT

Neural and subjective effects of inhaled N,N-dimethyltryptamine in natural settings

Using wireless EEG and psychometric questionnaires in 35 experienced participants in natural settings, inhaled N,N-dimethyltryptamine acutely reduced alpha (8–12 Hz) power across the scalp while increasing delta (1–4 Hz) and gamma (30–40 Hz) power, with gamma global synchrony and metastability rising as alpha measures fell. Gamma power increases correlated with mystical-type subjective reports, suggesting candidate EEG markers of such experiences and endorsing the value of field research on psychedelics.

Authors

  • Enzo Tagliazucchi
  • Robin Carhart-Harris
  • Christopher Timmermann

Published

Journal of Psychopharmacology
individual Study

Abstract

Background

N,N-dimethyltryptamine is a short-acting psychedelic tryptamine found naturally in many plants and animals. Few studies to date have addressed the neural and psychological effects of N,N-dimethyltryptamine alone, either administered intravenously or inhaled in freebase form, and none have been conducted in natural settings.

Aims

Our primary aim was to study the acute effects of inhaled N,N-dimethyltryptamine in natural settings, focusing on questions tuned to the advantages of conducting field research, including the effects of contextual factors (i.e. “set“ and “setting“), the possibility of studying a comparatively large number of subjects, and the relaxed mental state of participants consuming N,N-dimethyltryptamine in familiar and comfortable settings.

Methods

We combined state-of-the-art wireless electroencephalography with psychometric questionnaires to study the neural and subjective effects of naturalistic N,N-dimethyltryptamine use in 35 healthy and experienced participants.

Results

We observed that N,N-dimethyltryptamine significantly decreased the power of alpha (8–12 Hz) oscillations throughout all scalp locations, while simultaneously increasing power of delta (1–4 Hz) and gamma (30–40 Hz) oscillations. Gamma power increases correlated with subjective reports indicative of some features of mystical-type experiences. N,N-dimethyltryptamine also increased global synchrony and metastability in the gamma band while decreasing those measures in the alpha band.

Conclusions

Our results are consistent with previous studies of psychedelic action in the human brain, while at the same time the results suggest potential electroencephalography markers of mystical-type experiences in natural settings, thus highlighting the importance of investigating these compounds in the contexts where they are naturally consumed.

Unlocked with Blossom Pro

Research Summary of 'Neural and subjective effects of inhaled N,N-dimethyltryptamine in natural settings'

Editorial

βBlossom's Take

This paper is useful because it brings DMT physiology out of the lab and into a naturalistic setting, where set and setting can be examined rather than treated as noise. The wireless EEG findings, especially the alpha reduction with gamma changes linked to mystical-type reports, give a concrete field-based marker set for a short-acting psychedelic that has often been discussed more than measured.

Introduction

Pallavicini and colleagues situate their study within the recent resurgence of human research on serotonergic psychedelics, noting that prior laboratory work with compounds such as psilocybin, LSD and DMT has repeatedly reported broadband reductions in spontaneous oscillatory activity (particularly alpha-band) and increased signal diversity, alongside altered functional connectivity on fMRI. The authors highlight that most existing neurophysiological data come from controlled clinical or imaging settings, which limit ecological validity because psychedelic experiences are highly sensitive to 'set' (internal state) and 'setting' (external environment). They argue that naturalistic field investigations can capture contextual influences that laboratory experiments typically cannot, and that advances in mobile EEG make such recordings feasible. This study set out to characterise the acute neural and subjective effects of inhaled freebase DMT consumed in participants' preferred, self-chosen settings. The investigators combined wireless 24-channel EEG recordings with a battery of validated psychometric instruments to examine spectral power, signal diversity and measures of functional synchrony, and to relate these neural measures to detailed assessments of the subjective experience and of contextual factors such as intention, social setting and preparation.

Methods

This observational field study recruited 35 healthy, experienced participants (7 females; mean age 33.1 ± 6 years) between May and December 2019 by word-of-mouth and social media. Inclusion required at least two prior experiences with ayahuasca or DMT, abstinence from psychoactive substances (including alcohol, caffeine and tobacco) for at least 24 hours before the session, and willingness to consume DMT in the presence of four research team members. A non-diagnostic psychiatric interview screened for exclusionary conditions including psychotic or bipolar disorders (including family history), recent substance dependence (except nicotine), recurrent depressive or other specified diagnoses, neurological disorders, elevated baseline anxiety (more than 1 SD above the mean on the State-Trait Anxiety Inventory) and current psychiatric medication. Participants provided informed consent and determined the time and place of their DMT use; the research team did not supply the drug or direct how it was used. Participants consumed DMT freebase vapour derived from Mimosa hostilis recrystallised over non-psychoactive plant leaves (typical facilitator/participant estimate of pipe load ≈ 40 mg freebase). Most subjects were assisted by a facilitator and used their usual contextual elements (music, scents, lighting); four self-administered. Baseline EEG recordings comprised five minutes eyes open and five minutes eyes closed. Post-inhalation EEG began at exhalation and continued until the participant indicated a return to baseline (mean recording duration 6 ± 1.4 minutes). DMT presence in samples was confirmed by HPLC–mass spectrometry for profiling and qualitative analysis. Subjective measures administered immediately before and after the experience included the State-Trait Anxiety Inventory (STAI), a 12-item set assessing set/setting/intentions, the 5D-ASC (94 items), MEQ-30 (mystical experience), NDE (near-death experience) scale, a 27-item post-experience questionnaire addressing set/setting/social/fusion, the Big Five Inventory (BFI) and the Tellegen Absorption Scale (TAS). These instruments were used to quantify altered states, mystical-type experiences, near-death-like features, personality and absorption. EEG acquisition used a 24-channel wireless system (mBrainTrain) with electrodes at standard 10-20 sites; amplifier sampling rate was 500 Hz. Preprocessing in EEGLAB divided data into 2 s epochs, applied 1–90 Hz bandpass and a 47.5–52.5 Hz notch filter, and used automated plus manual inspection to flag and remove bad channels and epochs. Automated detection flagged on average 4.4 ± 1.8 channels per subject; manual inspection led to interpolation of rejected channels (mean 30% rejected channels, maximum 8). Epoch rejection averaged 21.3 ± 13.7 per subject. Infomax ICA was applied to remove eye and muscle components (mean 2.7 ± 1.1 components removed). Six participants were excluded from EEG analyses due to excessive artifact, leaving 29 subjects for spectral and complexity analyses. Spectral analyses computed logarithmic power spectral density (LPSD) in delta (1–4 Hz), theta (4–8 Hz), alpha (8–12 Hz), beta (12–30 Hz) and gamma (30–40 Hz) bands using FFT and time-frequency decomposition with Morlet wavelets. Signal diversity was estimated using the Lempel–Ziv complexity algorithm, and measures of coherence and metastability were derived to characterise synchrony and variability of oscillatory activity. Statistical comparisons used paired t-tests (DMT vs eyes-closed and vs eyes-open as appropriate) with multiple-comparison correction (Benjamini–Hochberg FDR or Bonferroni where stated). Correlations between EEG features and questionnaire scores used Pearson’s r and FDR correction, with significance at p<0.05 after correction.

Results

Participant-reported adequacy ratings of pre-experience factors averaged 71.4% ± 27.4% for 'set', 88.2% ± 10.1% for 'setting' and 53.9% ± 23.8% for 'clear intentions' (means ± SD expressed as % of maximum). On the 5D-ASC, the largest effects were in the visionary restructuralization domain (elementary imagery, complex imagery, audio–visual synesthesia) and in the blissful state facet of oceanic boundlessness; anxious ego dissolution items (impaired control, anxiety) were comparatively low. The NDE scale scored highest on its affective component. Using a 60% cut-off on each MEQ-30 subscale to define a 'complete mystical-type experience', 13 of 35 participants (37%) met this criterion. Comparing pre- to post-experience measures, agreeableness (BFI) and absorption (TAS) increased significantly, while state anxiety (STAI state) decreased. Baseline individual differences related to the acute response: 'clear intentions' correlated with the MEQ-30 mystical factor (R = 0.36, p = 0.029), baseline trait absorption correlated with the MEQ-30 mystical factor (R = 0.50, p = 0.005), and baseline neuroticism predicted the impaired control/cognition item on the 5D-ASC (R = 0.44, p = 0.007). Baseline state anxiety predicted both impaired control/cognition (R = 0.41, p = 0.012) and anxiety (R = 0.65, p = 0.001) during the DMT state. Spectral power analyses showed a widespread and significant attenuation of alpha-band (8–12 Hz) power under DMT compared with the eyes-closed baseline, with all electrodes exhibiting decreases. Relative to eyes-closed baseline, DMT also produced significant increases in low-frequency (< 3 Hz / delta) and high-frequency (> 36 Hz / gamma) power; no consistent changes were observed for theta or beta bands. Spatially, delta increases were most evident in occipital, parietal and anterior-central electrodes, whereas gamma increases were prominent in occipital, parietal and temporal regions. No significant differences were found between DMT and the eyes-open condition for overall power. Time-frequency analysis of the first seven minutes post-inhalation (mean EEG duration 6 ± 1.4 min) revealed that alpha power decreased most strongly in the first 40 s and returned progressively toward baseline, with statistically significant alpha reductions persisting until approximately 3 minutes after onset and LPSD differences approaching zero by about 7 minutes. The temporal evolution of alpha topographies showed non-uniform recovery across the scalp, with occipital and parietal electrodes exhibiting more persistent reductions. Correlational analyses relating subjective measures to band-specific LPSD found significant associations largely in the beta and gamma bands. Central beta power correlated positively with the 'anxiety' item of the 5D-ASC and with the 'cognition' component of the NDE scale across several regions. Occipital gamma power correlated with items including 'experience of unity', 'disembodiment' (5D-ASC), 'mystical' and 'transcendence of time and space' (MEQ-30) and the NDE 'cognition' item. Central, frontal and temporal gamma also showed positive correlations with subsets of mystical-type and imagery items. The temporal profiles of these correlations varied; some peaked early (around the peak subjective intensity) while others peaked later. Measures of functional synchrony and complexity differed under DMT: coherence and metastability decreased in the alpha band and increased in the gamma band when comparing DMT to eyes-closed baseline. Lempel–Ziv complexity increased across channels under DMT relative to eyes-closed, mirroring increases seen when comparing eyes-open to eyes-closed. The authors did not find significant correlations between the psychometric questionnaire scores and EEG coherence, metastability or Lempel–Ziv complexity.

Discussion

Pallavicini and colleagues interpret their findings as broadly consistent with prior laboratory reports of psychedelic-induced reductions in alpha power and increased signal diversity, while also identifying effects that may reflect the influence of naturalistic context. They emphasise that recruiting participants who had already planned and obtained DMT allowed a larger sample for field EEG recordings than many laboratory studies, and that the profile of subjective effects—especially prominent visionary restructuralization and strong affective NDE-like responses—resembled previous DMT reports. The authors highlight the notable association between increased gamma-band power and multiple questionnaire items indexing mystical-type and near-death-like phenomenology. They discuss possible interpretations carefully, noting that gamma activity can be contaminated by muscle artefacts (jaw clenching, microsaccades) but that the observed gamma effects persisted after conservative preprocessing and were spatially localised (predominantly occipital and central). They suggest that contextual factors related to set and setting might facilitate experiences whose neural correlates manifest in the gamma range, and point to converging but heterogeneous evidence from other psychedelic and meditative studies linking high-frequency synchrony to unitive or peak states. Differences in the temporal dynamics of alpha suppression compared with prior intravenous DMT work are considered in light of administration route and dose uncertainty: inhaled DMT may have faster clearance and shorter duration than intravenous dosing, and effective inhaled dose is difficult to quantify because combustion/inhalation efficiency is variable. The authors note an observed increase in delta power that diverges from some prior reports but accords with certain ayahuasca and animal studies; they attribute cross-study heterogeneity partly to differing pharmacological profiles and measurement approaches. Key limitations acknowledged by the study team include the impossibility of double-blinding and placebo control in this field design, lack of precise dose quantification and variable inhalation efficiency, potential expectation effects, and the decision not to collect follow-up data to preserve participant anonymity. The investigators frame field studies as complementary to controlled trials and large surveys: they argue that naturalistic recordings can illuminate how set, setting and intention interact with neurochemistry, and that such knowledge is relevant given the increasing unregulated therapeutic use of psychedelics. The authors conclude that wireless EEG can successfully record neural correlates of DMT experiences in real-world contexts and recommend future field studies to further probe interactions between context, subjective phenomenology and brain activity.

References (52)

Papers cited by this study that are also in Blossom

Classic hallucinogens and mystical experiences: phenomenology and neural correlates

Barrett, F. S., Griffiths, R. R. · Current Topics in Behavioral Neurosciences (2017)

265 cited
Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin

Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)

623 cited
Serotonergic psychedelics and personality: A systematic review of contemporary research

Bouso, J. C., Dos Santos, R. G., Hallak, J. E. · Neuroscience and Biobehavioral Reviews (2018)

133 cited
Dimethyltryptamine (DMT): Subjective effects and patterns of use among Australian recreational users

Cakic, V., Potkonyak, J., Marshall, A. · Drug and Alcohol Dependence (2010)

73 cited
Neural correlates of the LSD experience revealed by multimodal neuroimaging

Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)

875 cited
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)

1178 cited
The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs

Carhart-Harris, R. L., Leech, R., Shanahan, M. et al. · Frontiers in Human Neuroscience (2014)

1269 cited
The therapeutic potential of psychedelic drugs: past, present, and future

Carhart-Harris, R. L., Goodwin, G. M. · Neuropsychopharmacology (2017)

669 cited
The entropic brain - revisited

Carhart-Harris, R. L. · Neuropharmacology (2018)

539 cited
Show all 52 references
Psychedelics and the essential importance of context

Carhart-Harris, R. L., Roseman, L., Haijen, E. C. H. M. et al. · Journal of Psychopharmacology (2018)

634 cited
REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics

Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)

1128 cited
Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction

Garcia-Romeu, A., Griffiths, R. R., Johnson, M. W. · Current Drug Abuse Reviews (2015)

478 cited
Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers

Gouzoulis-Mayfrank, E., Heekeren, K., Neukirch, A. et al. · Pharmacopsychiatry (2005)

198 cited
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)

1671 cited
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects

Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)

934 cited
Predicting responses to psychedelics: a prospective study

Haijen, E. C. H. M., Kaelen, M., Roseman, L. et al. · Frontiers in Pharmacology (2018)

418 cited
180 cited
Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)

1173 cited
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function

Johnson, M. W., Hendricks, P. S., Barrett, F. S. et al. · Pharmacology and Therapeutics (2019)

518 cited
The hidden therapist: evidence for a central role of music in psychedelic therapy

Kaelen, M., Giribaldi, B., Raine, J. et al. · Psychopharmacology (2018)

270 cited
163 cited
Dynamic coupling of whole-brain neuronal and neurotransmitter systems

Kringelbach, M. L., Cruzat, J., Cabral, J. et al. · PNAS (2020)

320 cited
Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking

Kuypers, K. P. C., Riba, &. J., De La Fuente Revenga, &. M. et al. · Psychopharmacology (2016)

203 cited
LSD-induced entropic brain activity predicts subsequent personality change

Lebedev, A. V., Kaelen, M., L€ Ovd En, M. et al. · Human Brain Mapping (2016)

331 cited
Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness

Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)

904 cited
Neurochemical models of near-death experiences: A large-scale study based on the semantic similarity of written reports

Martial, C., Cassol, H., Charland-Verville, V, Erowid, E. et al. · Consciousness and Cognition (2019)

98 cited
Psychedelics, meditation, and self-consciousness

Milliere, R., Carhart-Harris, R. L., Roseman, L. et al. · Frontiers in Psychology (2018)

401 cited
Altered network hub connectivity after acute LSD administration

Müller, F., Dolder, P. C., Schmidt, A. et al. · NeuroImage (2018)

187 cited
Broadband Cortical Desynchronization Underlies the Human Psychedelic State

Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J. et al. · Journal of Neuroscience (2013)

498 cited
N,N-dimethyltryptamine and the pineal gland: Separating fact from myth

Nichols, D. E. · Journal of Psychopharmacology (2017)

68 cited
Tripping on nothing: placebo psychedelics and contextual factors

Olson, J. A., Suissa-Rocheleau, L., Lifshitz, M. et al. · Psychopharmacology (2020)

147 cited
The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network

Palhano-Fontes, F., Andrade, K. C., Tófoli, L.F. et al. · PLOS ONE (2015)

458 cited
A systematic study of microdosing psychedelics

Polito, V., Stevenson, R. J. · PLOS ONE (2019)

235 cited
Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting

Prochazkova, L., Lippelt, D. P., Colzato, L. S. et al. · Psychopharmacology (2018)

179 cited
Psychedelics and the human receptorome

Ray, T. S. · PLOS ONE (2010)

290 cited
Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers

Riba, J., Anderer, P., Morte, A. et al. · British Journal of Clinical Pharmacology (2002)

126 cited
The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers

Roseman, L., Leech, R., Feilding, A. et al. · Frontiers in Human Neuroscience (2014)

291 cited
Acute Biphasic Effects of Ayahuasca

Schenberg, E. E., Alexandre, J. F. M., Filev, R. et al. · PLOS ONE (2015)

115 cited
Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin

Schartner, M., Carhart-Harris, R. L., Barrett, A. B. et al. · Scientific Reports (2017)

444 cited
Psychometric evaluation of the altered states of consciousness rating scale (OAV)

Studerus, E., Gamma, A., Vollenweider, F. X. · PLOS ONE (2010)

685 cited
Prediction of psilocybin response in healthy volunteers

Studerus, E., Gamma, A., Kometer, M. et al. · PLOS ONE (2012)

370 cited
Increased global functional connectivity correlates with LSD-induced ego dissolution

Tagliazucchi, E., Roseman, L., Kaelen, M. et al. · Current Biology (2016)

525 cited
DMT models the near-death experience

Timmermann, C., Roseman, L., Williams, L. et al. · Frontiers in Psychology (2018)

225 cited
Neural correlates of the DMT experience assessed with multivariate EEG

Timmermann, C., Roseman, L., Schartner, M. et al. · Scientific Reports (2019)

321 cited
Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans

Valle, M., Maqueda, A. E., Rabella, M. et al. · European Neuropsychopharmacology (2016)

174 cited
Dimethyltryptamine (DMT): Prevalence, user characteristics and abuse liability in a large global sample

Winstock, A. R., Kaar, S., Borschmann, R. · Journal of Psychopharmacology (2013)

101 cited

Cited By (21)

Papers in Blossom that reference this study

Multi-metric evaluations of acute psychedelic effects on fMRI brain entropy

McCulloch, D. E. W., Olsen, A. S., Ozenne, B. et al. · Nature Communications (2026)

Predicting and exploring ayahuasca effects: Perception, mind-wandering, and EEG oscillations

Silva-Costa, N., Pessoa, J. A., Andrade, K. C. et al. · Journal of Psychopharmacology (2025)

Complex slow waves in the human brain under 5-MeO-DMT

Blackburne, G., Mcalpine, R. G., Fabus, M. et al. · Cell Reports (2025)

10 cited
Exploring 5-MeO-DMT as a pharmacological model for deconstructed consciousness

Timmermann, C., Sanders, J. W., Reydellet, D. et al. · Neuroscience of Consciousness (2025)

19 cited
DMT micro-phenomenology

Sanders, J. W., Milliere, R., Daily, Z. G. et al. · Preprints (2024)

3 cited
Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial

Falchi, M., Wießner, I., Silva, S. R. B. et al. · European Neuropsychopharmacology (2024)

24 cited
Synthetic surprise as the foundation of the psychedelic experience

De Filippo, R., Schmitz, D. · Neuroscience and Biobehavioral Reviews (2024)

13 cited
Show all 21 papers
Human brain effects of DMT assessed via EEG-fMRI

Timmermann, C., Roseman, L., Haridas, S. et al. · PNAS (2023)

213 cited
N,N-dimethyltryptamine affects EEG response in a concentration dependent manner - a pharmacokinetic/pharmacodynamic analysis

Eckernäs, E., Timmermann, C., Carhart-Harris, R. et al. · Philosophy and the Mind Sciences (2023)

15 cited
The Altered States Database: Psychometric data from a systematic literature review

Prugger, J., Derdiyok, E., Dinkelacker, J. et al. · Scientific Data (2022)

35 cited
53 cited
Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study

Cavanna, F., Muller, S., de la Fuente, L. A. et al. · Translational Psychiatry (2022)

127 cited
20 cited
Predictors and potentiators of psychedelic-occasioned mystical experiences

Gandy, S. · Journal of Psychedelic Studies (2022)

18 cited
Effects of Setting on Psychedelic Experiences, Therapies, and Outcomes: A Rapid Scoping Review of the Literature

Golden, T. L., Magsamen, S., Sandu, C. C. et al. · Current Topics in Behavioral Neurosciences (2022)

86 cited